Commure, a healthcare technology company, has secured US$200 million in growth financing from General Catalyst’s Customer Value Fund.

The funding will support Commure’s expansion and development of its healthcare technology products.

Commure offers AI-based tools for revenue cycle management, clinical documentation, and practice management.

Its solutions are used by over 130 health systems, including a recent large-scale rollout of ambient AI at HCA Healthcare.

The company aims to improve its products and expand its presence in the US healthcare market.

🔗 Source: Commure

🧠 Food for thought

1️⃣ AI revenue cycle management offers rapid financial returns for healthcare providers

Commure’s emphasis on AI-powered revenue cycle management aligns with a significant industry need, as hospitals currently lose approximately $20 billion annually due to claim denials alone 1.

Nearly half (46%) of hospitals have already implemented AI in their revenue cycle operations, with 74% utilizing some form of automation to address these financial challenges 2.

The return on investment is compelling and quick. Organizations implementing AI-driven RCM solutions can see measurable returns in as little as 40 days 3, while industry-wide adoption could potentially save healthcare $9.8 billion annually 4.

Commure’s focus on automating billing workflows end-to-end addresses the exact pain points healthcare systems are struggling with, from eligibility verification to payment posting, which explains their rapid growth serving 130+ health systems.

2️⃣ Mega-deals dominate digital health funding amid economic uncertainty

Commure’s $200 million funding round represents part of a larger trend where mega-deals (over $100 million) now account for 51% of all digital health funding, despite comprising only a small fraction of total deals 5.

While total digital health funding reached $6.3 billion in Q1 2025 (just a 2% increase year-on-year), the average deal size surged to $27 million—representing an 85% increase compared to the previous year 5.

This concentration of capital in fewer, larger deals suggests investors are becoming more selective, favoring established companies with proven revenue models and clear paths to profitability over earlier-stage ventures.